Pieris Pharmaceuticals

Filed a patent for "novel fusion protein specific for cd137 and cd228" on Wed, September 21, 2022

Filed a patent for "novel fusion protein specific for cd137 and cd228" on Tue, October 4, 2022

Filed a patent for "multimeric immunomodulator targeting 4-1bb" on Thu, July 20, 2023

Filed a patent for "biomarker methods and uses" on Thu, November 16, 2023

Filed a patent for "novel fusion protein specific for cd137 and cd228" on Mon, April 17, 2023

Filed a patent for "her2/4-1bb bispecific fusion proteins for the treatment of cancer" on Thu, May 23, 2024

Filed a patent for "novel lipocalin muteins specific for connective tissue growth factor (ctgf)" on Fri, October 6, 2023

Filed a patent for "her2/4-1bb bispecific fusion proteins for the treatment of cancer" on Fri, April 29, 2022